Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme that is involved in the metabolism of many drugs. Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated. This study aimed to investigate the inhibitory mechanism of TER and the differences in its inhibitory potency among three CYP2D6 variants, CYP2D6.1, CYP2D6.2, and CYP2D6.10. In a competitive inhibition study, the metabolic activity of the CYP2D6 was assessed based on their demethylation of dextromethorphan in the presence or absence of TER, and the time-dependency of the inhibitory effects were examined by preincubating the enzymes with TER. TER had weaker inhibitory effects on CYP2D6.2 and CYP2D6.10 than on CYP2D6.1; i.e., TER exhibited K<inf>i</inf> values (the concentration of inhibitor that results in half-maximal inhibition) of 0.0525, 0.355, and 1.85 μM for CYP2D6.1, CYP2D6.2, and CYP2D6.10, respectively. The inhibitory effects of TER were not time-dependent. Since TER's K<inf>i</inf> value for CYP2D6.10 was 35.2-fold higher than its K<inf>i</inf> value for CYP2D6.1, the CYP2D6 genotype of subjects should be taken into account when estimating the severity of drug interactions involving TER.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalDrug Metabolism and Pharmacokinetics
Volume30
Issue number4
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

terbinafine
Cytochrome P-450 CYP2D6
Drug Interactions
Dextromethorphan
Enzymes

Keywords

  • Drug interactions
  • Interindividual variation
  • Personalized medication
  • Time-dependent inhibition

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmaceutical Science

Cite this

Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6. / Akiyoshi, Takeshi; Ishiuchi, Miho; Imaoka, Ayuko; Ohtani, Hisakazu.

In: Drug Metabolism and Pharmacokinetics, Vol. 30, No. 4, 01.08.2015, p. 321-324.

Research output: Contribution to journalArticle

@article{8f52ff837828487c81c056dc7e86012f,
title = "Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6",
abstract = "Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme that is involved in the metabolism of many drugs. Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated. This study aimed to investigate the inhibitory mechanism of TER and the differences in its inhibitory potency among three CYP2D6 variants, CYP2D6.1, CYP2D6.2, and CYP2D6.10. In a competitive inhibition study, the metabolic activity of the CYP2D6 was assessed based on their demethylation of dextromethorphan in the presence or absence of TER, and the time-dependency of the inhibitory effects were examined by preincubating the enzymes with TER. TER had weaker inhibitory effects on CYP2D6.2 and CYP2D6.10 than on CYP2D6.1; i.e., TER exhibited Ki values (the concentration of inhibitor that results in half-maximal inhibition) of 0.0525, 0.355, and 1.85 μM for CYP2D6.1, CYP2D6.2, and CYP2D6.10, respectively. The inhibitory effects of TER were not time-dependent. Since TER's Ki value for CYP2D6.10 was 35.2-fold higher than its Ki value for CYP2D6.1, the CYP2D6 genotype of subjects should be taken into account when estimating the severity of drug interactions involving TER.",
keywords = "Drug interactions, Interindividual variation, Personalized medication, Time-dependent inhibition",
author = "Takeshi Akiyoshi and Miho Ishiuchi and Ayuko Imaoka and Hisakazu Ohtani",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.dmpk.2015.04.003",
language = "English",
volume = "30",
pages = "321--324",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "4",

}

TY - JOUR

T1 - Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6

AU - Akiyoshi, Takeshi

AU - Ishiuchi, Miho

AU - Imaoka, Ayuko

AU - Ohtani, Hisakazu

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme that is involved in the metabolism of many drugs. Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated. This study aimed to investigate the inhibitory mechanism of TER and the differences in its inhibitory potency among three CYP2D6 variants, CYP2D6.1, CYP2D6.2, and CYP2D6.10. In a competitive inhibition study, the metabolic activity of the CYP2D6 was assessed based on their demethylation of dextromethorphan in the presence or absence of TER, and the time-dependency of the inhibitory effects were examined by preincubating the enzymes with TER. TER had weaker inhibitory effects on CYP2D6.2 and CYP2D6.10 than on CYP2D6.1; i.e., TER exhibited Ki values (the concentration of inhibitor that results in half-maximal inhibition) of 0.0525, 0.355, and 1.85 μM for CYP2D6.1, CYP2D6.2, and CYP2D6.10, respectively. The inhibitory effects of TER were not time-dependent. Since TER's Ki value for CYP2D6.10 was 35.2-fold higher than its Ki value for CYP2D6.1, the CYP2D6 genotype of subjects should be taken into account when estimating the severity of drug interactions involving TER.

AB - Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme that is involved in the metabolism of many drugs. Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated. This study aimed to investigate the inhibitory mechanism of TER and the differences in its inhibitory potency among three CYP2D6 variants, CYP2D6.1, CYP2D6.2, and CYP2D6.10. In a competitive inhibition study, the metabolic activity of the CYP2D6 was assessed based on their demethylation of dextromethorphan in the presence or absence of TER, and the time-dependency of the inhibitory effects were examined by preincubating the enzymes with TER. TER had weaker inhibitory effects on CYP2D6.2 and CYP2D6.10 than on CYP2D6.1; i.e., TER exhibited Ki values (the concentration of inhibitor that results in half-maximal inhibition) of 0.0525, 0.355, and 1.85 μM for CYP2D6.1, CYP2D6.2, and CYP2D6.10, respectively. The inhibitory effects of TER were not time-dependent. Since TER's Ki value for CYP2D6.10 was 35.2-fold higher than its Ki value for CYP2D6.1, the CYP2D6 genotype of subjects should be taken into account when estimating the severity of drug interactions involving TER.

KW - Drug interactions

KW - Interindividual variation

KW - Personalized medication

KW - Time-dependent inhibition

UR - http://www.scopus.com/inward/record.url?scp=84938745817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938745817&partnerID=8YFLogxK

U2 - 10.1016/j.dmpk.2015.04.003

DO - 10.1016/j.dmpk.2015.04.003

M3 - Article

C2 - 26195224

AN - SCOPUS:84938745817

VL - 30

SP - 321

EP - 324

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 4

ER -